31P-NMR and differential scanning calorimetry studies for determining vesicle's drug physical state and fraction in alendronate liposomes

Journal of Bioanalysis and Biomedicine

Volumn 2, Issue 6, 2010, Pages 125-131

  Afergan, Eyal ^a   Najajreh, Yousef ^b   Gutman, Dikla ^a   Epstein, Hila ^a   Elmalak, Omar ^c   Golomb, Gershon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b AL QUDS UNIVERSITY   (Palestine)

^c Biorest Ltd   (Israel)

Author keywords

31P NMR; Alendronate; Differential scanning calorimetry (DSC); Encapsulation; Gallium nitrate; Liposomes

Indexed keywords

ALENDRONIC ACID; GALLIUM NITRATE; LANTHANIDE; LIPOSOME;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOSOMAL DELIVERY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 79952585735     PISSN: None     EISSN: 1948593X     Source Type: Journal    
DOI: 10.4172/1948-593X.1000035     Document Type: Article

References (28)

1. Adding LC, Bannenberg GL, Gustafsson LE (2001) Basic experimental studies and clinical aspects of gadolinium salts and chelates. Cardiovasc Drug Rev 19: 41-56.
2. Cea G, Bendahan D, Manners D, Hilton-Jones D, Lodi R, et al. (2002) Reduced oxidative phosphorylation and proton effl ux suggest reduced capillary blood supply in skeletal muscle of patients with dermatomyositis and polymyositis: a quantitative 31P-magnetic resonance spectroscopy and MRI study. Brain 125: 1635-1645.
3. Cohen-Sela E, Rosenzweig O, Gao J, Epstein H, Gati I, et al. (2006) Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release 113: 23-30.
4. Colombo A, Sangiorgi G (2004) The monocyte: the key in the lock to reduce stent hyperplasia? J Am Coll Cardiol 43: 24-26
5. Danenberg HD, Fishbein I, Epstein H, Waltenberger J, Moerman E, et al. (2003a) Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery. J Cardiovasc Pharmacol 42: 671-679.
6. Danenberg HD, Fishbein I, Gao J, Mönkkönen J, Reich R, et al. (2002) Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 106: 599-605.
7. Danenberg HD, Golomb G, Groothuis A, Gao J, Epstein H, et al. (2003b) Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 108: 2798-2804.
8. de Kruijff B, Cullis PR, Radda GK. (1975) Differential scanning calorimetry and 31P NMR studies on sonicated and unsonicated phosphatidylcholine liposomes. Biochim Biophys Acta 406: 6-20.
9. Epstein H, Afergan E, Moise T, Richter Y, Rudich Y, et al. (2006) Number-concentration of nanoparticles in liposomal and polymeric multiparticulate preparations: empirical and calculation methods. Biomaterials 27: 651-659.
10. Epstein H, Berger V, Levi I, Eisenberg G, Koroukhov N, et al. (2007) Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J Control Release 117: 322-332.
11. Epstein H, Gutman D, Cohen-Sela E, Haber E, Elmalak O, et al. (2008) Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization. AAPS J 10: 505-515.
12. Hinton DP, Johnson CS Jr. (1994) Simultaneous measurement of vesicle diffusion coefficients and trapping efficiencies by means of diffusion ordered 2D NMR spectroscopy. Chem Phys Lipids 69: 175-178.
13. Hoffer P (1980) Gallium: mechanisms. J Nucl Med 21: 282-285.
14. Li X, Hirsh DJ, Cabral-Lilly D, Zirkel A, Gruner SM, et al. (1998) Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1415: 23-40.
15. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK (1992) A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 86: III47-52.
16. Lin JH, Russell G, Gertz B (1999) Pharmacokinetics of alendronate: an overview. Int J Clin Pract Supp 101: 18-26.
17. Mayhew E, Ahmad I, Bhatia S, Dause R, Filep J, et al. (1997) Stability of association of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with liposomes is composition dependent. Biochim Biophys Acta 1329: 139-148.
18. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53: 283-318.
19. Nelson JA, Bennett LH, Wagner MJ (2002) Solution synthesis of gadolinium nanoparticles. J Am Chem Soc 124: 2979-2983.
20. Noseworthy MD, Bray TM (1998) Effect of oxidative stress on brain damage detected by MRI and in vivo 31P-NMR. Free Radic Biol Med 24: 942-951.
21. Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55: 329-347.
22. Rodan GA (1998) Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 38: 375-388.
23. Seydel JK (1991) Nuclear magnetic resonance and differential scanning calorimetry as tools for studying drug-membrane interactions. Trends Pharmacol Sci 12: 368-371.
24. Thomas PG, Verkleij AJ (1990) The dissimilar interactions of the calcium antagonist fl unarizine with different phospholipid classes and molecular species: a differential scanning calorimetry study. Biochim Biophys Acta 1030: 211-222.
25. Torchilin V, Weissig PV (1990) Liposomes: A prcticale approach, Boston, Oxford University Press
26. Web (2009) http://clinicaltrials.gov/ct2/show/NCT00739466.
27. Zhang J, Wilke N, Wang Y, Zhang Y, Wang C, et al. (1996) Functional and bioenergetic consequences of postinfarction left ventricular remodeling in a new porcine model. MRI and 31 P-MRS study. Circulation 94: 1089-1100.
28. Zhang XM, Patel AB, de Graaf RA, Behar KL. (2004) Determination of liposomal encapsulation efficiency using proton NMR spectroscopy. Chem Phys Lipids 127: 113-120.